Acrivon Therapeutics, Inc. reported a net loss of $77.9 million for the year ended December 31, 2025, compared to a net loss of $80.6 million for the previous year. The company, a clinical-stage biopharmaceutical firm, has not generated any revenue to date and anticipates continued significant expenses as it advances its drug candidate pipeline. As of December 31, 2025, Acrivon had an accumulated deficit of $274.9 million. The company's operations are primarily funded through proceeds from the sale of shares, convertible notes, and private placements.
Research and development expenses totaled $60.0 million in 2025, a decrease from $64.0 million in 2024. This decrease was mainly due to fewer milestones incurred in the ACR-368 clinical trial, offset by increased costs related to ACR-2316, a novel clinical-stage asset, and personnel-related expenses. General and administrative expenses decreased to $24.1 million in 2025 from $25.2 million in 2024, primarily due to lower payroll and professional fees. Total other income, net, decreased from $8.6 million in 2024 to $6.2 million in 2025, mainly due to lower interest income on investments.
Operationally, Acrivon is focused on advancing its lead program, ACR-368, through Phase 2b clinical trials, with a focus on endometrial cancer. Interim clinical data from the ACR-368-201 trial showed a confirmed overall response rate of 39% in Arm 1 for endometrial cancer. The company is also progressing ACR-2316, a dual WEE1/PKMYT1 inhibitor, through a Phase 1 monotherapy clinical trial. In January 2026, initial clinical data was reported, with two weekly oral dosing regimens established and clinical activity observed, including a confirmed partial response in a subject with endometrial cancer. The company is also advancing ACR-6840, an internally discovered development candidate targeting CDK11, in IND enabling studies for planned IND filing in the fourth quarter 2026.
A significant strategic development was the termination of the companion diagnostic agreement with Akoya, with Acrivon bringing OncoSignature testing in-house through its newly certified CLIA laboratory. This move is expected to enhance capabilities and efficiencies in supporting the development of targeted therapeutic agents. As of December 31, 2025, Acrivon had 76 full and part-time employees, with a majority engaged in research and development activities. The company believes its existing cash, cash equivalents, and investments of $118.6 million as of December 31, 2025, will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2027.
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines using its proprietary AP3 proteomics platform. The company designs targeted cancer therapies and companion OncoSignature diagnostics to identify patients most likely to respond, focusing on tumors beyond genomics-based selection. Its pipeline includes selective inhibitors like ACR-368 and ACR-2316, aimed at treating solid tumors with high unmet needs through biomarker-driven patient stratification and rational drug combinations.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.